Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults

Registry study (n=90,094) found those taking SGLT2i had similar major adverse CV event risk (HR 0.98 [95% CI 0.87, 1.10], decreased hospitalisation for heart failure (HR 0.68 [95% CI 0.57, 0.80]); but increased risk of diabetic ketoacidosis & lower limb amputations vs. GLP1.

Diabetes Care